Inovio Pharmaceuticals (NYSE:INO) CEO Jong Joseph Kim purchased 25,000 shares of the stock in a transaction dated Tuesday, April 15th. The stock was purchased at an average cost of $2.25 per share, for a total transaction of $56,250.00. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares after opening at $2.62 moved to $2.80on last trade day and at the end of the day closed at $2.65. Company price to sales ratio in past twelve months was calculated as 47.14and price to cash ratio as 12.10. Inovio Pharmaceuticals Inc (NYSEMKT:INO) showed a negative weekly performance of -0.75%.
The global bio pharmaceutical company Celgene Corporation (NASDAQ:CELG) bought 714,286 shares of biomedical company Alliqua (NASDAQ:ALQA) for $5,000,002. Celgene Corporation (NASDAQ:CELG) shares advanced 1.95% in last trading session and ended the day on $146.64. CELG return on equity ratio is recorded as 25.80% and its return on assets is 11.50%. Celgene Corporation (NASDAQ:CELG) yearly performance is 15.61%.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Director Bruce Kovner bought 1,250,000 shares of Synta Pharmaceuticals Corp. stock on the open market in a transaction dated Friday, April 11th. The shares were purchased at an average price of $4.01 per share, for a total transaction of $5,012,500.00.Synta Pharmaceuticals Corp. (NASDAQ:SNTA) shares moved up 9.48% in last trading session and was closed at 4.39 while trading in range of $4.10 – $4.39 – Synta Pharmaceuticals Corp. (NASDAQ:SNTA) year to date (YTD) performance is 34.41%.
OHR Pharmaceutical (NASDAQ:OHRP) Director June Sherie Almenoff acquired 5,500 shares of OHR Pharmaceutical stock in a transaction dated Tuesday, April 8th. The stock was purchased at an average cost of $10.25 per share, for a total transaction of $56,375.00. OHR Pharmaceutical Inc (NASDAQ:OHRP) on last trading day company shares ended up $9.79. OHR Pharmaceutical Inc (NASDAQ:OHRP) distance from 50-day simple moving average (SMA50) is -32.54 %. Analysts mean target price for the company is $21.00.
Leave a Reply